natgillin/translations-raw huggingface dataset:
Use as claimed in any of claims 1 to 24, combination as claimed in claim 28, composition as claimed in claim 29, compound as claimed in claim 30 or product as claimed in claim 31, wherein the bacterial infection is an infection with methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae or multiple resistant Enterococcus faecium. 
Uporaba prema bilo kojem od zahtjeva 1 do 24, kombinacije kako je zatraženo u zahtjevu 28, pripravka kako je zatraženo u zahtjevu 29, spoja kako je zatraženo u zahtjevu 30 ili proizvoda kako je zatraženo u zahtjevu 31, naznačena time da bakterijska infekcija je infekcija sa bakterijom Staphilococcus aureus (MRSA) rezistentnom na meticilin, koagulaza negativnim na meticilin rezistentnim stafilokokom (MRCNS), Streptococcus pneumoniae rezistentne na penicilin ili višestruko rezistentne Enterococcus faecium.
at least one pore in the parylene coating, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the body; 
(c) najmanje jednu poru u parilenskoj oblozi, gdje se najmanje jedna pora pruža od vanjske površine parilenske obloge do površine tijela.
According to still another embodiment, the pigment has a specific surface area of greater than 25 m2/g, a d50 value from 0.3 to 3 um and a porosity, when in form of a compacted bed, of greater or equal to 35%. 
Tiskovna podloga prema zahtjevu 3, naznačena time da pigment ima specifičnu površinu veću od 25 m'/g, ds vrijednost od 0.3 do 3 um i poroznost, kada je u kompaktnom obliku, veću ili jednaku 35 %.
A pharmaceutical composition comprising a crystalline form of a compound of Formula XI substantially in the form of Form 1 characterized by an X-ray diffraction pattern having characterizing peaks at about 9.2 and 13.0 on the 20 scale, in combination with an anti-tumor agent or a signal transduction inhibitor. 
Kristalni oblik spoja formule XI [image] bitno u obliku oblika 1, 2-(2-fluoro-4-jodofenilamino)-N-(2-hidroksietoksi)-1,5-dimetil-6-okso-1,6-dihidropiridin-3-karboksamid naznačen time da uzorkom rendgenske difrakcije koja ima karakterizirajuće šiljke na oko 9.2 i 13.0 na skali 2θ.
The method according to claim 16, wherein sufficient nitrogenous base is added to raise the pH to be in the range of about 2.5 to about 6.5. 
Postupak prema zahtjevu 15, naznačen time, da se dodaje dovoljno dušične baze, da bi se dostigla pH, u rasponu od 3.0-4.0.
The method of manufacture of the catheter tube (10) according to any one of the claims 14 to 19, wherein the method further comprises a subsequent step of coating a primary outer surface (16) of the catheter tube (10) with a lubrication material. 
Postupak izrade reverzibilne kateterske cijevi (10) prema bilo kojem od zahtjeva 11 do 13 pri čemu postupak nadalje obuhvaća naknadni korak premazivanja primarne vanjske površine (16) reverzibilne kateterske cijevi (10) premazom.
The explosion proof and environment protective gas refueling equipment of any one of Claims 12-18, characterized in that the material unit is covered with a metal protective mesh. 
Oprema za nadolijevanje plina koja je otporna na eksploziju i štiti okoliš prema zahtjevu 6, naznačena time da je jedinica materijala (1) prekrivena s metalnom zaštitnom mrežom (W).
The peptide according to claim 1 or 2, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid uključuje nepeptidne veze.
The system of claim 9, wherein the fourth software module, configured to determine if the attribute of the parsed field matches the valid characteristic of the valid corresponding field, is further configured to determine (60) if the attribute of the parsed field is valid for a predetermined operating system. 
Sustav prema zahtjevu 9, naznačeno time da je četvrti softverski modul, konfiguriran za popravak (106) nevažećeg polja, konfiguriran za statistički popravak (116) nevažećeg polja uključujući: modificiranje (118) slike prijenosne izvršne datoteke na medij pohrane; i pohranu (120) modificirane slike na medij pohrane.
the prevention of reactivation of tuberculosis; or the delay of reactivation of tuberculosis. 
(c) sprječavanje reaktiviranja tuberkuloze; ili (d) odgađanje reaktiviranja tuberkuloze.
* green-to-blue, 5 layers design, Cr/MgF2 /Ni/MgF2/Cr as disclosed in patent US 4,838,648; obtained form FLEX Products Inc., Santa Rosa, CA. 
* zelena-do-plave, uzorak od 5 slojeva, Cr/MgF2/Ni/MgF2/Cr kako je opisano u patentu US 4,838,648; dobavljeno od tvrtke FLEX Products Inc., Santa Rosa, CA.
The video decoding method of claim 1, wherein the maximum split information for the inter mode is obtained as parameters with respect to one data level from among data levels comprising a picture sequence, a picture, a slice, and a data unit for encoding a video. 
Uređaj za dekodiranje video zapisa prema zahtjevu 1, naznačen time što se informacija o maksimalnom dijeljenju za transformacijsku jedinicu s intra načinom dobije kao parametri u odnosu na jednu razinu podataka između razina podataka koje sadrže niz slika, sliku, odsječak, 1 jedinicu podataka za kodiranje videa.
A Compound of formula (I) wherein X is OR2 or R3, and wherein R2 and R3 are a C1-C6 linear or branched alkyl, C3-C6 cycloalkyl, C6 aryl, optionally substituted with a group selected from the group consisting of methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, t-butyl and phenyl. 
Spoj s formulom (I) naznačen time da X je OR2 ili R3, i pri čemu R2 i R3 su C1-C6 ravni ili razgranati alkil, C3-C6 cikloalkil, C6 aril, proizvoljno supstituiran sa skupinom odabranom iz skupine koju čine metil, etil, n-propil, i-propil, n-butil, sec-butil, t-butil i fenil.
The method according to claim 16, characterized in that subsequent to the comminution step, the calcium carbonate particles are subjected to a classification step. 
Postupak prema zahtjevu 16, naznačen time da se nakon koraka usitnjavanja, čestice kalcijevog karbonata podvrgavaju koraku razvrstavanja.
The cable fixture device according to claim 8, wherein the supporting material has a material being one selected from the group consisting of a metal, a plastic and a combination thereof. 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 8, naznačena time da je nosivi dio (93, 97) od materijala koji je jedan odabran iz skupine koja sadrži metal, plastiku i njihove kombinacije.
mg of a white solid were obtained (yield: 52%). 
Dobiveno je 300 mg bijele krute tvari (prinos: 52 %).
a polypeptide having an amino acid sequence having a 90% or more homology with an amino acid sequence of SEQ ID NO: 1 or 2, and exhibiting a TBC1D1 activity, 
polipeptida sa sekvencom aminokiselina s 90%-tnom ili većom homologijom i sekvencom aminokiselina SEQ ID NO: 1 ili 2; koji pokazuje aktivnost TBC1D1,
Mucous surfaces suitable for application of the emulsions of the present invention can include corneal, conjunctival, buccal, sublingual, nasal, vaginal, pulmonary, stomachic, intestinal, and rectal routes of administration. 
HR P20161251 T1 intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, bolusnog, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog, ili transdermalnog uređaja za isporuku ili sustava.
heating the solution resulting from step (vi) to a temperature of about 50 to 100° C. in about 0.15 to 30 minutes; 
(vli)zagrijavanje otopine dobivene u koraku (vi) do temperature od 50 do 100%C kroz 0.15 do 30 minuta;
Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities. 
Neke pomoćne tvari i aktivni sastojci skloni su prijanjati površini žiga i boje, što može uzrokovati brazdanje i druge površinske nepravilnosti.
5-((4-(4-fluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide, or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios. 
-((4-(4-fluorfenil)piperidin-3-il)amino)kinazolin-8-karboksamid, ili njegovi stereoizomeri ili tautomeri, ili farmaceutski prihvatljive soli svakog od navedenih, uključujući njihove smjese u svim omjerima.
The method of claim 1, wherein the first average oil droplet size is 5000 nm or less. 
Postupak prema zahtjevu 1, naznačen time da je prva prosječna veličina uljne kapljice 5000 nm ili manje.
In one aspect, the invention is directed to a rapamycin carbohydrate derivative having the structure of formula (I): 
U jednom aspektu, ovaj izum usmjeren je na ugljikohidratni derivat rapamicina čija je struktura formule (T):
A dose counter according to any preceding claim, wherein the actuator shaft is resiliently biased towards a starting position, the actuator shaft being displaceable against the resilient bias for actuating the dose counter. 
Brojač doza u skladu s bilo kojim od patentnih zahtjeva 1 ili 5, pri čemu je pokretačka osovina (20) elastično odmaknuta prema početnoj poziciji, pokretačka osovina (20) se može odmaknuti naspram elastičnog pomaka za pokretanje brojača doza.
The extended release dosage form of claim 95, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevu 12, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji sadrži, bazirano na reološkim mjerenjima, približnu molekulsku težinu od barem
a sense strand comprising at least 15 contiguous nucleotides from SEQ ID NO: 1295; and 
dsRNA prema zahtjevu 4, naznačena time da sense lanac sadrži sekvencu iz SEQ ID NO:1295.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent to obtain a compound of formula IIb in the form of diastereoisomeric mixture (R,S+S,S) 
I) reakciju 2,2-dimetil-1,3dioksolan-4-karbaldehida formule dq s vinil Grignardovim reagensom, da bi se dobio spoj formule IIb u obliku dijasteroizomerne smjese (R, S+8, S) on
The method of claim 1, wherein the compound is 6-bromo-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6-bromo-8-(metil-D3)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina.
The glatiramer acetate and the rasagiline for use according to claim 34, wherein the glatiramer acetate and the rasagiline are administered sequentially at an interval of up to 24 hours. 
Glatiramer acetat i rasagilin za uporabu u skladu s patentnim zahtjevom 34, naznačeni time, da se glatiramer acetat i rasagilin daju sekvencijalno u intervalu do 24 sata.
The method of claim 1, the prodrug compound is represented by a structure of Formula 7 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
i 8. Sastav iz patentnog zahtjeva 1, tvar sadrži strukturu Formule 7 ili njen stereoizomer ili njenu farmaceutski s
as well as the corresponding N-hydroxysuccinimidyl esters, or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers. 
kao i odgovarajući N-hidroksisukcinimidilni esteri, ili njihove farmaceutski prihvatljive soli, hidrati, ili hidratirane soli, ili polimorfne kristalne strukture tih spojeva ili njihovih optičkih izomera, racemata, dijastereomeri ili enantiomeri.
at least one coupling means (5), to connect said at least one propelling means and said at least one suction means; 
- najmanje jedno spojno sredstvo (5) koja povezuje navedeno najmanje jedno pogonsko sredstvo (4) s navedenim najmanje jednim usisnim sredstvom (3);
The antibody as defined in any one of claims 1 to 3 for use in the prophylaxis and treatment of inflammatory and thrombotic disorders according to claim 11, wherein said disorder is peripheral arterial occlusive disease (PAOD) or critical limb ischemia (CLI). 
Protutijelo prema bilo kojem zahtjevu od 1 do 4 ili 9, naznačeno time, da se upotrebljava za profilaksu ili liječenje upalnih 1 trombotičkih poremećaja prema zahtjevu 13, pri čemu je spomenuti poremećaj okluzivna bolest perifernih arterija (PAOD) ili opasna ishemija ekstremiteta (CLI).
In a further preferred embodiment, step (d) is carried out for a duration within a range of about 5 minutes to about 30 minutes. 
U daljnjoj poželjnoj izvedbi, korak (d) se provodi tijekom vremenskog raspona od oko 5 min pa do 30 min.
When tightened against member 49 the lock nut 64 forces the protuberance 54 into frictional engagement with shoulder 56, thereby preventing rotation of adjuster nut 26 relative to shank 52 . 
Kada se pojača opterećenje na član 49 zabravljujuća navrtka 64 prinudno dovodi ispupčenja 54 u frikcijski kontakt s ramenom 56, sprečavajući time okretanje navrtke 26 za podešavanje u odnosu na osovina 52.
at least one pore in the parylene coating, wherein the at least one pore extends from an outer surface of the parylene coating to the surface of the head portion of the body; 
(ili) najmanje jedna pora u parilenskoj oblozi, gdje se najmanje jedna pora pruža od vanjske površine parilenske obloge do površine glave tijela.
PBDs are of the general structure: 
Broj objave europskog patenta:
Modular antibody according to any one of claims 1 to 3, wherein said antigen binding site is located in the range of amino acids 7 to 21, amino acids 25 to 39, amino acids 41 to 81, amino acids 83 to 85, amino acids 89 to 103 and amino acids 106 to 117, wherein the numbering is according to the IMGT numbering scheme. 
Modularno protutijelo prema bilo kojem zahtjevu od 1 do 3, naznačeno time, da je spomenuto mjesto vezanja antigena postavljeno u rasponu aminokiselina od 7 do 21, aminokiselina od 25 do 39, aminokiselina od 41 do 81, aminokiselina od 83 do 85, aminokiselina od 89 do 103 1 aminokiselina od 106 do 117, pri čemu numeriranje odgovara brojčanoj shemi IMTG.
Example 1 kg of crushed, washed and dried flakes from waste-PET bottles were given into the hopper of a twin screw extruder. 
Primjer 1 300 kg zdrobljenih, ispranih 1 osušenih pahuljica od otpadnih PET boca stavi se u lijevak za punjenje dvopužnog ekstrudera.
The immunogenic composition of claim 17 further comprising an adjuvant. 
Imunogenski sastav prema zahtjevu 17 koji nadalje sadrži adjuvans.
Typically, this oligofructose has a DP ranging from 3 to 5. 
U tipičnom slučaju, DP te oligofruktoze kreće se u rasponu od 3 do 5.
The composition of claim 5, wherein the protein is P-glycoprotein, MDR-2, or MDR-3. 
Sastav zahtjeva 3, time naznačeno da je protein P-glikoprotein, MDR-2 ili MDR-3.
Subsequent to said slicing process, a waste board 10 remains which is also termed as "backing board" being shown in Fig. 17. 
Nakon navedenog postupka rezanja kriški, ostaje otpadna ploča 10 koja se naziva također i "uporišna ploča" koja je prikazana na slici 17.
Structure according to claim 10, in which the insulating surround (12) is also suitable for overlapping the door frame (32) in such a way that from the exterior only the glazing (50) of the frame is visible. 
Struktura prema zahtjevu 10, naznačena time da je izolacijsko okruženje (12) također pogodno za prekrivanje okvira vrata (32) na takav način da je izvana vidljivo samo ostakljenje okvira.
Brief description of the drawings 
«» PRIJEVOD PATENTNIH ZAHTJEVA EUROPSKOG PATENTA
Use of a product according to claim 40 in mixing and/or extruding and/or compounding and/or blow moulding with plastic materials, and preferably with polyolefins or thermoplastics such as polyethylene (PE), polypropylene (PP), polyurethanes (PU) and polyvinylchloride (PVC) 
Uporaba proizvoda prema bilo kojem zahtjevu od 1 do 13 naznačena time da je za miješanje i/ili ekstrudiranje i/ili slaganje i/ili puhanje plastičnih materijala, te poželjno za poliolefine ili termoplastike kao što su polietilen (PE), polipropilen (PP), poliuretani (PU) i polivinilklorid (PVC).
There are slight amounts of 2′,7-bis-TBDMS, but this is not a significant amount. 
Postoje male količine 2',7-bis-TBDMS, no to nije značajna količina.
a fully human Fab fragment; or a fully human F(ab)2 fragment. 
(1ii) potpuno humanog Fab fragmenta; ili (iv) potpuno humanog F(ab)2 fragmenta.
In such a valve according to the invention with an inner cavity filled with liquid, the liquid preferably flows through the transmission during a translatoric movement of the spindle. 
Ventil (1, 32) u skladu s bilo kojim od patentnih zahtjeva 6 i 7, karakteriziran na način da tekućina protječe kroz prijenos za vrijeme translacijskog gibanja osovine (21, 44).
The system according to any of claims 1 to 7 wherein at least one base plate unit (20) and an insulation material (50) form a pre-insulated prefabricated part. 
Sustav temeljem bilo kojeg od zahtjeva 1 do 7 pri čemu barem jedna jedinica bazne ploče (20) 1 izolacijski materijal (50) tvore unaprijed izolirani predgotovljeni dio.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation when subjected to an indentation test has a "penetration depth to crack distance" of at least about 1.0 mm. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži 8 mg hidromorfon hidroklorida, te najmanje oko 94 % (težinski) polietilen oksida.
The nonwoven fabric according to claim 13, wherein the compound units are arranged in staggered rows. 
Netkani materijal prema zahtjevu 10, naznačen time da su prvo i drugo mnoštvo spojenih dijelova raspoređeni u naizmjeničnim redovima.
A method of passing smoke and/or mist through a network of conduits of a deluge fire extinguishing system for testing openness of the deluge fire extinguishing system. 
Postupak testiranja otvorenih, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara, obuhvaća sljedeće korake koji se izvode bilo kojim prikladnim redom:
The process according to any one of claims 6 to 15, wherein the lipase from Candida is from Candida cylindracea (CCL) or from Candida antartica of type B (CALB). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedena lipaza iz kvasca Candida lipaza iz kvasca Candida cylindracea (CCL) ili Candida antartica tip B (CALB).
The DART molecule of paragraph 22, wherein said tumor-associated antigen is a breast cancer antigen, an ovarian cancer antigen, a prostate cancer antigen, a cervical cancer antigen, a pancreatic carcinoma antigen, a lung cancer antigen, a bladder cancer antigen, a colon cancer antigen, a testicular cancer antigen, a glioblastoma cancer antigen, an antigen associated with a B cell malignancy, an antigen associated with multiple myeloma, an antigen associated with non-Hodgkins lymphoma, or an antigen associated with chronic lymphocytic leukemia. Paragraph 24. 
Molekula diatijela prema zahtjevu 13, naznačena time što antigen povezan s tumorom je antigen karcinoma dojke, antigen karcinoma jajnika, antigen karcinoma prostate, antigen karcinoma vrata maternice, antigen karcinoma gušterače, antigen karcinoma pluća, antigen karcinoma mjehura. antigen karcinoma debelog crijeva, antigen karcinoma testisa, antigen karcinoma glioblastoma, antigen povezan s malignitetom B stanica, antigen povezan s multiplim mijelomom, antigen povezan s ne-Hodgkinovim limfomom, ili antigen povezan s kroničnom limfocitnom leukemijom. Molekula diatijela prema zahtjevu 13, naznačena time što antigen povezan s tumorom je A33; ADAM-9; ALCAM;
the zinc-responsive host cell is an SP2/0 cell. 
€) stanica koja je osjetljiva na cink je stanica SP2/0.
Tubby (tub/tub) mice are characterized by obesity, moderate insulin resistance and hyperinsulinemia without significant hyperglycemia [Coleman et al, Heredity (1990) 81:424]. 
Tubby (tub/tub) miševi su karakterizirani debljinom, promjenjivom inzulinskom rezistencijom i hiperinzulinemijom bez signifikantne hiperglikemije [Coleman et al, Heredity (1990) 81:424].
Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-positive bacterium selected from Staphylococcus spp., Streptococcus spp., Propionibacterium spp., Enterococcus spp., Bacillus spp., Corynebacterium spp., Nocardia spp., Clostridium spp., Actinobacteria spp., and Listeria spp.. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-pozitivnom bakterijom izabranom od Staphylococcus spp., Streptococcus spp., Propionibacterium spp., Enterococcus spp., Bacillus spp., Corynebacterium spp., Nocardia spp., Clostridium spp., Actinobacteria spp. i Listeria spp.
The method of claim 10, wherein the composition comprises 500-5,000 ug/mL of sodium hyaluronate or hyaluronic acid. 
Farmaceutski oblik za uporabu prema zahtjevu 5, gdje farmaceutski oblik sadrži natrijev hijaluronat ili hijaluronsku kiselinu u terapijski učinkovitoj koncentraciji od 500-5,000 ug/mL.
A pharmaceutical composition comprising a compound having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier. 
ili njegova farmaceutski prihvatljiva sol; i farmaceutski prihvatljivo sredstvo za razrjeđivanje ili nosač.
A pharmaceutical composition for use in the treatment of headache comprising 4-9 weight parts of Radix Angelicae Sinensis, 4-9 weight parts of Rhizoma Chuanxiong, 2-8 weight parts of Radix Paeoniae alba, 2-8 weight parts of Radix Rehmanniae Preparata, 10-15 weight parts of Ramulus Uncariae cum Uncis, 10-15 weight parts of Caulis Spatholobi, 10-15 weight parts of Spica Prunellae, 10-15 weight parts of Semen Cassiae, 10-15 weight parts of Concha Margaritifera Usta, 4-9 weight parts of Rhizoma Corydalis and 0.5-2 weight parts of Herba Asari, characterized in that said composition is prepared by a method as follows: 
Farmaceutski pripravak za uporabu u liječenju glavobolje koji sadržava 4 do 9 težinskih udjela Radix Angelicae Sinensis, 4 do 9 težinskih udjela Rhizoma Chuanxiong, 2 do 8 težinskih udjela Radix Paeoniae alba, 2 do 8 težinskih udjela Radix Rehmanniae Preparata, 10 do 15 težinskih udjela Ramulus Uncariae cum Uncis, 10 do 15 težinskih udjela Caulis Spatholobi, 10 do 15 težinskih udjela Špica Prunellae, 10 do 15 težinskih udjela Semen Cassiae, 10 do 15 težinskih udjela Concha Margaritifera Usta, 4 do 9 težinskih udjela Rhizoma Corydalis i 0,5 do 2 težinskih udjela Herbe Asari, naznačen time, da se navedeni pripravak priprema sljedećim postupkom:
Dosage form for use according to any of embodiments 7 to 12, wherein the dosage form comprises said amount or half of said amount dissolved in an application fluid in a dosing unit, the amount being dependent on whether said amount is provided by administration to one nostril or by administration to two nostrils. 
Oblik doziranja za uporabu prema bilo kojem od zahtjeva 5 do 10, naznačen time da oblik doziranja sadrži navedenu količinu ili polovicu navedene količine otopljenu u tekućini za primjenu jedinici za doziranje, te je količina ovisna o tome da li je navedena količina predviđena za primjenu na jednu nosnicu ili za primjenu na dvije nosnice.
The compound for use according to claim 8, wherein A is selected from the group consisting of 
Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran iz skupine koja se sastoji od [image]